Testosterone Replacement Therapy in Elderly Males with Hypogonadism

Diagnostic Confirmation Required Before Treatment

Testosterone replacement therapy (TRT) should only be initiated in elderly men after confirming both biochemical hypogonadism (morning total testosterone <300 ng/dL on two separate occasions measured between 8-10 AM) and specific symptoms, primarily diminished libido and erectile dysfunction. 1, 2

Essential Diagnostic Steps

Measure morning total testosterone (8-10 AM) on at least two separate days to confirm persistent hypogonadism, as single measurements are unreliable due to assay variability and diurnal fluctuation 1, 3
If total testosterone is borderline (275-350 ng/dL), measure free testosterone by equilibrium dialysis and sex hormone-binding globulin (SHBG), especially in men with obesity or diabetes where low SHBG may artificially lower total testosterone 1
Measure LH and FSH to distinguish primary (testicular) from secondary (pituitary-hypothalamic) hypogonadism, which has critical treatment implications for fertility preservation 1
Assess for reversible causes: obesity, uncontrolled diabetes, sleep apnea, medications (opioids, glucocorticoids), thyroid dysfunction, and hyperprolactinemia 1

Primary Indication: Sexual Function Improvement

The primary evidence-based indication for TRT in elderly men is diminished libido and erectile dysfunction, with small but significant improvements (standardized mean difference 0.35). 1, 4, 3

Realistic Expectations for Treatment Outcomes

Sexual function and libido: Small but significant improvement (SMD 0.35), typically noticeable within 3-6 months 1, 4, 3
Physical functioning, energy, vitality: Little to no effect (SMD 0.17 for energy/fatigue)—do not expect meaningful improvements 1, 4
Depressive symptoms: Less-than-small improvement (SMD -0.19)—insufficient for clinical depression 1
Cognition and memory: No demonstrated benefit 1, 4
Metabolic benefits: Modest improvements in insulin resistance, HbA1c reduction of ~0.37%, and lipid profile 1, 4
Bone mineral density: Modest improvement at lumbar spine (3.2% increase), minimal at femoral neck (1.4% increase) 5

Treatment Selection Algorithm

First-Line: Transdermal Testosterone Gel

Transdermal testosterone gel 1.62% at 40.5 mg daily (applied to shoulders and upper arms) is the preferred first-line formulation for elderly men due to stable day-to-day testosterone levels and lower erythrocytosis risk compared to injectable forms. 1, 2

Advantages of Transdermal Preparations

More stable testosterone levels without supraphysiologic peaks or subtherapeutic troughs 1
Lower risk of erythrocytosis (3-18%) compared to injectable testosterone (up to 44%) 4
Easily titratable with dose adjustments between 20.25 mg (1 pump) and 81 mg (4 pumps) 2
Preferred for elderly patients and those with cardiovascular risk factors 1, 4

Critical Safety Warning for Transdermal Gel

Children and women must never touch unwashed application sites—secondary exposure causes virilization in children (early puberty, genital enlargement) and unwanted masculinization in women 2
Patients must wash hands immediately with soap and water after application 2
Cover application sites with clothing after gel dries 2
Wash application site thoroughly before any skin-to-skin contact with others 2

Second-Line: Intramuscular Testosterone Injections

If cost is a primary concern, intramuscular testosterone cypionate or enanthate 100-200 mg every 2 weeks is more economical (annual cost $156 vs. $2,135 for gel), but carries higher erythrocytosis risk. 1

Dosing and Monitoring for Injectable Testosterone

Standard dosing: 100-200 mg every 2 weeks or 50-100 mg weekly 1
Peak levels occur days 2-5, return to baseline by days 10-14 1
Measure testosterone levels midway between injections (days 5-7), targeting mid-normal range of 500-600 ng/dL 1
Higher risk of erythrocytosis (up to 44%) requires more frequent hematocrit monitoring 4

Absolute Contraindications to TRT

TRT is absolutely contraindicated in the following situations: 1, 4, 3

Active desire for fertility preservation—use gonadotropin therapy (hCG plus FSH) instead, as testosterone causes prolonged azoospermia 1
Active or treated male breast cancer 1
Known or suspected prostate cancer 3
Hematocrit >54% 1, 4
Untreated severe obstructive sleep apnea 1
Recent myocardial infarction or stroke within past 3-6 months 6
Severe or decompensated heart failure 6

Monitoring Requirements During Treatment

Initial Monitoring (First Year)

Testosterone levels: Measure at 2-3 months after initiation or dose change, then every 6-12 months once stable 1, 3
- For transdermal gel: measure any time after 2-3 months of stable therapy 1
- For injectable testosterone: measure midway between injections (days 5-7) 1
- Target mid-normal range: 500-600 ng/dL 1
Hematocrit/hemoglobin: Monitor at baseline, 2-3 months, then every 6-12 months 1, 4
- Withhold treatment immediately if hematocrit >54% 1, 4
- Consider dose reduction if hematocrit 52-54% 1
- Consider therapeutic phlebotomy in high-risk patients with persistent elevation 1
PSA and digital rectal examination: Baseline in men >40 years, then every 6-12 months 1, 4
- Refer for urologic evaluation if PSA increases >1.0 ng/mL in first 6 months or >0.4 ng/mL per year thereafter 1
Clinical symptom assessment: Evaluate sexual function, libido, and overall quality of life 1, 3
- Discontinue TRT at 12 months if no improvement in sexual function—do not continue without demonstrated benefit 1

Management of Erythrocytosis on TRT

Erythrocytosis is the most common serious adverse effect of TRT, particularly with injectable formulations, and requires systematic management. 1, 4

Hematocrit-Based Management Algorithm

Hematocrit 50-52%: Continue current therapy with closer monitoring every 3 months; consider dose reduction if trending upward 1
Hematocrit 52-54%: Reduce testosterone dose by 25-50%; consider switching from injectable to transdermal formulation 1
Hematocrit >54%: Withhold testosterone therapy immediately; consider therapeutic phlebotomy (remove 500 mL every 1-2 weeks until hematocrit <52%) in high-risk patients 1, 4

Formulation Switching Strategy

If erythrocytosis develops on injectable testosterone, switch to transdermal gel or patch, which provides more stable levels and lower erythrocytosis risk (3-18% vs. up to 44%) 1, 4

Special Considerations for Elderly Men

Cardiovascular Risk Considerations

The cardiovascular safety of TRT in elderly men remains controversial, with conflicting evidence. 5, 4

The TOM trial (2010) showed increased cardiovascular adverse events in men >65 years with mobility limitations receiving TRT (23 vs. 5 events), though this finding has not been replicated in other high-quality studies 5
Multiple subsequent studies and meta-analyses show neutral or possibly beneficial cardiovascular effects 4, 6
Avoid TRT in men with recent MI or stroke (<3-6 months) or severe/decompensated heart failure 6
Target mid-range testosterone levels (350-600 ng/dL) rather than upper-normal in elderly patients with cardiovascular risk factors 1

Obesity-Associated Secondary Hypogonadism

Before initiating TRT in obese elderly men with secondary hypogonadism, attempt weight loss through low-calorie diets and regular exercise, as this can improve testosterone levels without medication. 1, 6

Weight loss of 5-10% can significantly increase endogenous testosterone production 1
If lifestyle modifications fail after 4-6 months and symptoms persist with confirmed low testosterone, proceed with TRT 1

Frailty and Physical Function

Do not initiate TRT in elderly men primarily for improving physical function, muscle strength, or frailty, as evidence shows minimal to no benefit. 5, 1, 4

Studies in frail elderly men show no significant improvements in upper- or lower-extremity strength, physical performance, or frailty assessments despite modest increases in lean body mass 5
The primary indication remains sexual dysfunction, not physical performance 1

Critical Pitfalls to Avoid

Never diagnose hypogonadism based on symptoms alone—biochemical confirmation with two morning testosterone measurements is mandatory 1, 6
Never start TRT without confirming the patient does not desire fertility—testosterone causes prolonged azoospermia; use gonadotropin therapy instead 1
Never ignore mild erythrocytosis (hematocrit 50-52%) in elderly patients—even modest elevations increase blood viscosity and thrombotic risk in this population 1
Never continue TRT beyond 12 months without documented improvement in sexual function—discontinue if no benefit to prevent unnecessary long-term exposure to risks 1
Never use TRT in eugonadal men (testosterone >300 ng/dL) for "anti-aging," weight loss, or improving energy—this violates evidence-based guidelines and exposes patients to unnecessary risks 1, 3
Never assume age-related testosterone decline requires treatment—approximately 20-30% of men >60 years have low-normal testosterone, but this does not constitute disease requiring treatment without specific symptoms 1

Duration of Treatment and Reassessment

TRT should continue only as long as the patient experiences meaningful clinical benefit (primarily improved sexual function) that outweighs risks, with decisions made on an individual basis. 6

Reassess clinical response at 3,6, and 12 months after initiation 6
If no improvement in sexual function by 12 months, discontinue TRT 1
For responders, continue monitoring at least yearly with testosterone levels, hematocrit, PSA, and clinical symptom assessment 1, 6
Consider withdrawal if hypogonadism is reversed after resolution of underlying disorder (e.g., significant weight loss, discontinuation of offending medications) 6

What is the recommended approach to testosterone replacement therapy (TRT) in an elderly male with hypogonadism?

Help us tailor your experience